20 to 50     : Dose as in normal renal function
10 to 20     : Dose as in normal renal function
<10           : Dose as in normal renal function
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unknown dialysability. Dose as in normal renal function
HD                     :Unknown dialysability. Dose as in normal renal function
HDF/high flux   :Unknown dialysability. Dose as in normal renal function
CAV/VVHD      :Unknown dialysability. Dose as in normal renal function
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
Antibacterials: metabolism accelerated by rifampicin; metabolism possibly inhibited by erythromycin
Anticoagulants: efficacy of coumarins may be altered
Anti-epileptics: metabolism accelerated by carbamazepine, barbiturates, phenytoin and primidoneAntifungals: increased risk of hypokalaemia with amphotericin – avoid concomitant use; metabolism possibly inhibited by itraconazole and ketoconazoleA
ntivirals: concentration possibly increased by ritonavir
Ciclosporin: rare reports of convulsions in patients on ciclosporin and high-dose corticosteroids
Cytotoxics: increased risk of haematological toxicity with methotrexate
Diuretics: enhanced hypokalaemic effects of acetazolamide, loop diuretics and thiazide diuretics
Vaccines: high-dose corticosteroids can impair immune response to vaccines; avoid concomitant use with live vaccines
ADMINISTRATION
Reconstition
–
Route
Orally, IV, IM, topically
Rate of Administration
IV bolus: over half to one minute
Comments
Can be added to glucose 5% or sodium chloride 0.9%
OTHER INFORMATION
750 micrograms betamethasone ≡ 5 mg prednisolone
Even when applied topically, sufficient corticosteroid may be absorbed to give a systemic effec
tEffects of betamethasone on sodium and water retention are less than those of prednisolone and approximately equal to those of dexamethasone